Clinical Edge Journal Scan

PsA-associated fatigue correlates with QoL, functional impairment, and disease activity


 

Key clinical point: Fatigue is a prevalent phenomenon among patients with psoriatic arthritis (PsA) and strongly correlated with quality of life (QoL), disease activity, and levels of serum interleukin-17 (IL-17).

Major finding: Level of PsA disease activity was significantly correlated with measures of fatigue, functional capacity, and QoL ( P less than .001). Moreover, QoL ( P = .001), disease activity ( P = .019), and serum IL-17 ( P = .029) were significant independent predictive factors for fatigue.

Study details: The findings come from an analysis of 80 adults with PsA from the outpatient clinics of Physical Medicine, Rheumatology, & Rehabilitation Department, Tanta University Hospitals randomly selected during the period from December 2019 to August 2020.

Disclosures: This study did not receive any funding. All the authors declared no conflicts of interest.

Source: Gado SE et al. Expert Rev Clin Immunol. 2021 Apr 2. doi: 10.1080/1744666X.2021.1905522.

Recommended Reading

Debate: Should biologics be used for milder cases of psoriasis?
Psoriatic Arthritis ICYMI
Psoriasis associated with an increased risk of COVID-19 in real-world study
Psoriatic Arthritis ICYMI
Safety and efficacy of upadacitinib in patients refractory to nonbiologic DMARDs
Psoriatic Arthritis ICYMI
OPAL Balance trial confirms long-term safety and efficacy of tofacitinib
Psoriatic Arthritis ICYMI
Guselkumab yields higher enthesitis resolution rates
Psoriatic Arthritis ICYMI
Comparative efficacy of guselkumab, IL-17A, and TNF inhibitors
Psoriatic Arthritis ICYMI
PsA: Women have more severe disease than men
Psoriatic Arthritis ICYMI
Comorbidity rates higher with PsA than psoriasis alone
Psoriatic Arthritis ICYMI
Imaging should be the preferred modality for detecting enthesitis in PsA with concurrent fibromyalgia
Psoriatic Arthritis ICYMI
TNF-α inhibitors outperform IL-12/23 antagonists and PDE4 therapy
Psoriatic Arthritis ICYMI